wepoker下载

    • 日本語

      Our Mission
      Inclusive and Open to Diversity,
      Innovationoriented to Win Together
      and Benefit the Mankind

      Haihe Biopharma
      Pioneering the Future
      of Original
      Oncology Drugs

      Haihe Stories
      Our Scientists

      Haihe Mission

      Our Mission and Purpose

      Research and Development

      More R&D Pipelines

      Haihe Stories

      Our Scientists

      About Us

      • Established in

        2011

      • Headquartered in

        Pudong

        Shanghai

        China

      • China

        Indigenous

        Innovative

        Biopharma

        Company

      • Specializing in the Discovery,

        Development, Production

        and Commercialization

        Innovative Oncology

        Drugs

      • Academician1

        Scientists100

        Doctorate
        Degree        25

        Number of
        Employees        134

        Master’s
        Degree        37


        As of DEC.31,2025

      • Core Products

        in R&D Pipeline

        10+

       
      R&D Field
      Strong, Innovation-driven R&D Capabilities
      • Have obtained multiple proprietary global intellectual property rights
      • Multiple global clinical research projects are ongoing simultaneously
      • Have been recognized by authoritative industry institutions
      Cancer Types Covered by the R&D Pipeline
      Lung Cancer
      Breast Cancer
      Gastric Cancer
      Gynecological Cancer
      Rich and Balanced Pipeline
      • 1 product – Gumarontinib, an oral highly selective mesenchymal-epithelial transition (MET) inhibitor and a Category 1 innovative new chemical drug has been conditionally approved by NMPA that Haihe owns its global intellectual property rights.
      • 10+ Oncology+Non-oncology compounds in core pipeline, including those in late clinical stage and pre-clinical stage
      • Multiple potential best-in-class compounds are expected to be used in monotherapy or combination to treat major indications
      Company Milestones

      Haihe Biopharma is an innovation-driven biotechnology company in China focusing on the discovery, development, production and commercialization of innovative anti-tumor drugs. Haihe brings life-saving therapies to cancer patients worldwide. 

      •  

        March 2023

        Haihe Biopharma’s Gumarontinib has been approved by NMPA

      •  

        March 2022

         NMPA-CDE Grants Priority Review Designation to Haihe Biopharma's Gumarontinib

      •  

        February 2022

        The NDA for Haihe Biopharma’s Gumarontinib has been accepted for review by the CDE.

      •  

        March 2021

        Haihe established its Japan office

      •  

        July 2020

        Haihe completed the reorganization of related group companies. Shanghai Haihe Pharmaceutical Research and Development Co Ltd acquired the stakes of Shanghai RMX Biopharma Co Ltd.

      •  

        December 2019

        Haihe established its US office

      •  

        October 2019

        Haihe’s Manufacturing Hub set foot in Taizhou China Medical City, with planned investment of 600 million yuan

      •  

        April 2019

        Haihe completed the first patient dosing of oral paclitaxel RMX3001 phase III clinical trial for advanced gastric cancer

      •  

        September 2018

        Haihe reached strategic cooperation agreements with Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Tigermed, Junshi Biosciences, 3D Medicines, and Jiuzhou Pharmaceutical

      •  

        March 2018

        Haihe Pharmaceutical merged with Nuomaixi Pharmaceutical to form Haihe Biopharma Co, Ltd.

      Interviews
      I am glad that some research achievements in China in the field of oncology drugs have already been on par with global leaders. Especially in personalized research, China is carrying out projects concurrently with the world, and striving to be a leader in certain aspects.

      Academician Jian Ding:
      Make Good Drugs that Ordinary People Can Afford

      （Xinmin Evening News，2020-11-18）

      Read More
       
      I often tell myself to work hard and seize every opportunity. I also often inspire my team to develop good drugs that ordinary people can afford, so that new drugs created by Chinese scientists will come onto the global stage as soon as possible.
      News Center
      Join Us
      Let’s ride the wave of developing original innovative drugs in China. Haihe Biopharma aspires to become one of the companies that R&D professionals and outstanding managers have the strongest desire to join.
      Follow Us
      ? 2020 All Rights Reserved Haihe Biopharma Co., Ltd.
      沪ICP备12016151号-1
      【网站地图】【sitemap】